To determine if a combination of human blood DC subsets can efficiently polarize T cells into effector cells that are favorable for cancer immunotherapy, CD1c+ DCs and/or pDCs were used to activate allogeneic naive CD4+ or CD8+ T cells. The gene discussed is CD1C; the disease is cancer.